@article {PECTASIDES2317, author = {D. PECTASIDES and M. NIKOLAOU and E. PECTASIDES and A. KOUMARIANOU and C. VALAVANIS and TH. ECONOMOPOULOS}, title = {Complete Response after Imatinib Mesylate Administration in a Patient with Chemoresistant Stage IV Seminoma}, volume = {28}, number = {4C}, pages = {2317--2320}, year = {2008}, publisher = {International Institute of Anticancer Research}, abstract = {The case of a young man with stage IV chemoresistant pure seminoma overexpressing KIT, who achieved complete remission (CR) after the administration of imatinib mesylate (400 mg once daily), along with a third-line chemotherapy regimen, consisting of paclitaxel (150 mg/m2), oxaliplatin (100 mg/m2) and gemcitabine (800 mg/m2) every 2 weeks with granulocyte colony-stimulating factor (G-CSF) support is reported. The patient had received first- and second-line regimens consisting of ifosfamide, bleomycin, etoposide cisplatin (5 cycles, every 3 weeks) and methotrexate, vinblastine, actinomycin D, cyclophosphamide, cisplatin (3 cycles, every 3 weeks) respectively, without having normalized β-human chorionic gonadotrophin (β-HCG) levels. Following treatment with imatinib plus third-line chemotherapy (paclitaxel, oxaliplatin, gemcitabine), the levels of β-HCG were reduced to within the normal limits during the first month of treatment. Therefore, the patient underwent surgical resection of the residual disease from the retroperitoneum and liver, which proved to be only necrotic tissue. The patient is under close follow-up, with no evidence of disease, 36 months after the completion of chemotherapy and 32 months post surgery. Copyright{\textcopyright} 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/28/4C/2317}, eprint = {https://ar.iiarjournals.org/content/28/4C/2317.full.pdf}, journal = {Anticancer Research} }